Experimental blood cancer drug KK2430 enters first human tests

NCT ID NCT07629726

Recruiting now Disease control Sponsor: Kyowa Kirin Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study is the first time the experimental drug KK2430 is being tested in humans. It aims to find out if KK2430 is safe, how the body processes it, and whether it can help treat blood cancers. About 72 adults with blood cancers that have not responded to other treatments will receive the drug intravenously. The study is currently recruiting participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KK2430 (an experimental drug given intravenously)
What this could lead to: If this trial succeeds, it could point toward a new treatment option for people with blood cancers.
What could go wrong: This is a very early, first-in-human study with only 72 participants. The drug may not work or could have serious side effects. It will take years before any potential treatment is available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC NEOPLASMS

Contacts and locations

Locations

Prisma Health
RECRUITING

Greenville, South Carolina, 29605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.